Vascular News and Research

RSS

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Presence of albumin in urine predicts cognitive decline: Study

A new study has found that low amounts of albumin in the urine, at levels not traditionally considered clinically significant, strongly predict faster cognitive decline in older women.

21 Nov 2010

Gore joins vascular, endovascular leaders to honor physicians receiving annual recognition

W. L. Gore & Associates joined with leaders from across the vascular and endovascular community to honor a distinguished group of eight physicians receiving the 2010 Pioneers in Performance Awards.

20 Nov 2010

Medtronic's implantable device delivers positive results for abdominal aortic aneurysms treatment

An implantable medical device used in the minimally invasive treatment of abdominal aortic aneurysms, the Endurant Stent Graft System from Medtronic, Inc., delivered strong results through one year of patient follow-up in the company's U.S. pivotal study, according to clinical data presented at VEITHsymposium.

20 Nov 2010

Gore sponsors EVEResT Lunch Symposium

W. L. Gore & Associates is sponsoring the EVEResT (European Virtual Reality Endovascular Research Team) Lunch Symposium taking place on Friday, Nov. 19 from 12:00 to 1:00 p.m. at the VEITHsymposium in the Gramercy A room, second floor. The symposium will detail the evidence for simulation in medical training and in other fields. Companies will demonstrate how new simulation technologies are designed to enhance performance in endovascular procedures.

20 Nov 2010

Scientists discover Notch pathway may play a role in alcohol's protective effects

Many studies support the assertion that moderate drinking is beneficial when it comes to cardiovascular health, and for the first time scientists have discovered that a well-known molecule, called Notch, may be behind alcohol's protective effects. Down the road, this finding could help scientists create a new treatment for heart disease that mimics the beneficial influence of modest alcohol consumption.

20 Nov 2010

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

P.A.D. occurs when arteries in the legs become narrowed or clogged with fatty deposits, reducing blood flow to the legs. This can result in leg muscle pain when walking, disability, amputation, and poor quality of life. Blocked arteries found in people with P.A.D. can be a red flag that other arteries, including those in the heart and brain, may also be blocked - increasing the risk of a heart attack or stroke.

20 Nov 2010

Scientist suggests functional amino acids play a critical role in human health

Functional amino acids play a critical role in the development of both animals and humans, according to a Texas AgriLife Research scientist.

20 Nov 2010

Boston Scientific signs definitive agreement to acquire Sadra Medical

Boston Scientific Corporation today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire Sadra Medical, Inc., a development-stage company in Los Gatos, California. Sadra is developing the first fully repositionable device for percutaneous aortic valve replacement to treat patients with severe aortic stenosis.

20 Nov 2010

Medtronic's Valiant Stent System effective for thoracic aortic aneurysms treatment

An implantable medical device used in the minimally invasive treatment of thoracic aortic aneurysms, the Valiant Thoracic Stent Graft System from Medtronic, Inc., delivered strong results through 30 days of patient follow-up in the company's U.S. pivotal study, according to clinical data presented at VEITHsymposium.

19 Nov 2010

Boston Scientific's CRT-Ds, ICDs receive CE Mark approval

Boston Scientific Corporation today announced CE Mark approval of its INCEPTA, ENERGEN and PUNCTUA cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators.

19 Nov 2010

Stromedix obtains license from UCSF for integrin αvβ5 antibody

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.

19 Nov 2010

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

Discovery of a fifth gene defect and the identification of 47 DNA regions linked to thoracic aortic disease are the subject of studies released this month involving researchers at The University of Texas Health Science Center at Houston.

19 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

Study compares effect on HT status in mid, late life on dementia risk

Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.

19 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that an interim analysis of all 86 patients enrolled in the company's Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.

19 Nov 2010

St. Jude Medical completes acquisition of AGA Medical

St. Jude Medical, Inc. today announced that it has successfully completed its acquisition of AGA Medical Holdings, Inc.

19 Nov 2010

Study finds adverse long term health effects of E coli infection

People who contract gastroenteritis from drinking water contaminated with E coli are at an increased risk of developing high blood pressure, kidney problems and heart disease in later life, finds a study published online in the British Medical Journal.

19 Nov 2010

Vascular News and Research

VYTORIN reduces major vascular events in patients with chronic kidney disease

Presence of albumin in urine predicts cognitive decline: Study

Gore joins vascular, endovascular leaders to honor physicians receiving annual recognition

Medtronic's implantable device delivers positive results for abdominal aortic aneurysms treatment

Gore sponsors EVEResT Lunch Symposium

Scientists discover Notch pathway may play a role in alcohol's protective effects

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

Scientist suggests functional amino acids play a critical role in human health

Boston Scientific signs definitive agreement to acquire Sadra Medical

Medtronic's Valiant Stent System effective for thoracic aortic aneurysms treatment

Boston Scientific's CRT-Ds, ICDs receive CE Mark approval

Stromedix obtains license from UCSF for integrin αvβ5 antibody

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Study compares effect on HT status in mid, late life on dementia risk

OXiGENE updates data on FALCON trial for non-small cell lung cancer

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

St. Jude Medical completes acquisition of AGA Medical

Study finds adverse long term health effects of E coli infection

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News